    Mary Rozenman | Aimmune Therapeutics, Inc. | ZoomInfo.com﻿

























Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 45,060 Shares of Stock - BNB Daily





































 
















 

 













Daily Ratings & News for Aimmune Therapeutics Inc.
Complete the form below to receive the latest headlines and analysts' recommendationsfor Aimmune Therapeutics Inc. with our free daily email newsletter:



 




Follow @bnbdailynews





Recent Posts

HighTower Advisors LLC Purchases 42 Shares of Rogers Corporation (ROG)
Nuveen Asset Management LLC Has $2.12 Million Stake in Aaron’s, Inc. (NYSE:AAN)
CF Industries Holdings, Inc. (CF) Shares Bought by Nomura Asset Management Co. Ltd.
Nomura Asset Management Co. Ltd. Sells 420 Shares of Avery Dennison Corporation (AVY)
DnB Asset Management AS Has $974,000 Stake in Unum Group (UNM)
KAMES CAPITAL plc Holds Position in T. Rowe Price Group, Inc. (TROW)
Fisher Asset Management LLC Raises Stake in Bio-Rad Laboratories, Inc. (BIO)
Atria Investments LLC Sells 334 Shares of Camden Property Trust (CPT)
Exxonmobil Investment Management Inc. TX Has $3.27 Million Position in Red Hat, Inc. (RHT)
Fisher Asset Management LLC Boosts Position in Cemex S.A.B. de C.V. (CX)
Fisher Asset Management LLC Decreases Position in Umpqua Holdings Corporation (UMPQ)
Livforsakringsbolaget Skandia Omsesidigt Has $315,000 Stake in Dollar Tree, Inc. (DLTR)
Macerich Company (The) (MAC) Position Raised by Xact Kapitalforvaltning AB
Xact Kapitalforvaltning AB Boosts Position in Bunge Limited (BG)
Positive Press Coverage Somewhat Unlikely to Affect TransCanada Corporation (NYSE:TRP) Share Price
Telecom Argentina Stet – France Telecom (NYSE:TEO) Getting Somewhat Favorable Media Coverage, Study Finds
TIER REIT (OTCMKTS:TIER) Earns Daily News Sentiment Rating of 0.42
Trinity Biotech PLC (TRIB) Given Media Impact Score of 0.18
Landec Corporation (LNDC) Earns Daily Coverage Optimism Score of 0.34
Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 45,060 Shares of Stock


 


Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 45,060 Shares of Stock

Posted by Dan Jones on Jul 25th, 2017 // No Comments 

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 45,060 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $20.85, for a total value of $939,501.00. Following the completion of the sale, the insider now owns 30,129 shares in the company, valued at approximately $628,189.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 
Shares of Aimmune Therapeutics, Inc. (AIMT) opened at 22.00 on Tuesday. Aimmune Therapeutics, Inc. has a one year low of $11.52 and a one year high of $27.31. The company’s 50-day moving average price is $19.91 and its 200-day moving average price is $19.92. The company’s market capitalization is $1.11 billion. 


 Get Aimmune Therapeutics Inc. alerts:



Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.05. On average, equities research analysts predict that Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current year. 
COPYRIGHT VIOLATION NOTICE: This article was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.baseball-news-blog.com/2017/07/25/aimmune-therapeutics-inc-aimt-insider-mary-m-rozenman-sells-45060-shares-of-stock-updated-updated.html. 




A number of research analysts recently weighed in on AIMT shares. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Tuesday, May 16th. ValuEngine raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aimmune Therapeutics currently has an average rating of “Buy” and an average price target of $33.00.
A number of institutional investors have recently added to or reduced their stakes in AIMT. Franklin Street Advisors Inc. NC acquired a new position in Aimmune Therapeutics during the first quarter valued at about $450,000. State Street Corp boosted its position in Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock valued at $11,782,000 after buying an additional 193,272 shares during the period. Russell Investments Group Ltd. acquired a new position in Aimmune Therapeutics during the fourth quarter valued at about $1,711,000. Renaissance Technologies LLC acquired a new position in Aimmune Therapeutics during the fourth quarter valued at about $2,100,000. Finally, Palo Alto Investors LLC boosted its position in Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares during the period. 69.62% of the stock is currently owned by institutional investors and hedge funds. 
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. 

 
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 





















Latest News




Leave a Reply

Click here to cancel reply.




Name (Required) 



Mail (will not be published) (Required) 



Website






 






























﻿






























Mary M. Rozenman Sells 14,940 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for Aimmune Therapeutics Inc.

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor Aimmune Therapeutics Inc. with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

Hancock Holding Company (NASDAQ:HBHC) Stake Cut by Bank of America Corp DE
STORE Capital Corporation (NYSE:STOR) Shares Sold by Bank of America Corp DE
Weiss Multi Strategy Advisers LLC Cuts Position in The Charles Schwab Corporation (SCHW)
Vertex Pharmaceuticals Incorporated (VRTX) to Post Q2 2017 Earnings of $0.11 Per Share, Leerink Swann Forecasts
Cabela’s Inc (CAB) Shares Bought by Schwab Charles Investment Management Inc.
National Instruments Corporation (NATI) Shares Bought by Schwab Charles Investment Management Inc.
Q2 2017 EPS Estimates for Pinnacle West Capital Corporation (NYSE:PNW) Lifted by Analyst
Community Bank System, Inc. (CBU) Shares Sold by Amalgamated Bank
Amalgamated Bank Acquires 176 Shares of Dril-Quip, Inc. (DRQ)
Stanley Black & Decker’s (SWK) “Equal Weight” Rating Reaffirmed at Morgan Stanley
Q3 2017 Earnings Forecast for USG Corporation (USG) Issued By SunTrust Banks
Renaissance Technologies LLC Has $11.83 Million Stake in Sigma Designs, Inc. (SIGM)
CEVA, Inc. (NASDAQ:CEVA) Shares Sold by New York State Teachers Retirement System
PBF Energy Inc. (NYSE:PBF) Stake Decreased by Morgan Stanley
UBS AG Reiterates Buy Rating for O’Reilly Automotive, Inc. (ORLY)
$4.86 Earnings Per Share Expected for Intuitive Surgical, Inc. (NASDAQ:ISRG) This Quarter
O’Reilly Automotive, Inc. (ORLY) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
Northland Securities Reaffirms “Buy” Rating for Starcom PLC (STAR)
Photo-Me International plc (PHTM) Rating Reiterated by FinnCap
FinnCap Reiterates Corporate Rating for Zoo Digital Group plc (ZOO)







Mary M. Rozenman Sells 14,940 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock


					Posted by Chloe McGuire on Jul 19th, 2017 // No Comments




Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 14,940 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $21.44, for a total transaction of $320,313.60. Following the completion of the sale, the insider now directly owns 9,103 shares of the company’s stock, valued at $195,168.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. 
Shares of Aimmune Therapeutics, Inc. (AIMT) opened at 21.65 on Wednesday. The firm has a 50-day moving average of $19.36 and a 200-day moving average of $19.89. The company’s market capitalization is $1.09 billion. Aimmune Therapeutics, Inc. has a 12 month low of $10.66 and a 12 month high of $27.31. 


 Get Aimmune Therapeutics Inc. alerts:



Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.05.  On average, equities analysts predict that  Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current year. 





COPYRIGHT VIOLATION WARNING: “Mary M. Rozenman Sells 14,940 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was  posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/07/19/mary-m-rozenman-sells-14940-shares-of-aimmune-therapeutics-inc-aimt-stock.html. 
A number of brokerages have issued reports on AIMT. Piper Jaffray Companies  reaffirmed an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, March 22nd. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Two research analysts have rated the stock with a hold rating and four have assigned  a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $33.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. purchased a new position in shares of  Aimmune Therapeutics during the first quarter valued at about $1,064,000.  Swiss National Bank boosted its position in shares of  Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares during the period.  Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of  Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the period.  C WorldWide Group Holding A S purchased a new position in shares of  Aimmune Therapeutics during the first quarter valued at about $4,087,000.  Finally, Nationwide Fund Advisors boosted its position in shares of  Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares during the period. 69.64% of the stock is owned by institutional investors and hedge funds. 
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.







Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 





















































Rozenman Mary M. - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1648920 - Address: Aimmune Therapeutics, Inc., 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005-1884 10 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


S%ret113514142823017S%wins000000 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/17/17 16:317/13/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaM.dm453.020150D
7/17/17 16:317/13/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaS.dm-32021.440-15-990D
7/6/17 17:017/3/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaM.dm1363.020450D
7/6/17 17:017/3/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaS.dm-93920.850-45-1000D
11/4/16 16:0811/4/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaM.d733.022240D-72627-10-219402858
11/4/16 16:0811/4/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaS.d-42417.602-24-1000D-72627-10-219402858
10/7/16 16:0510/5/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaM.d763.023250D-181857145783183521
10/7/16 16:0510/5/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaS.d-42016.803-25-1000D-181857145783183521
9/9/16 16:059/8/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaM.d913.023300D-27518371912133274541
9/9/16 16:059/8/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsRozenman Mary M.CAOSee RemaS.d-50416.803-30-1000D-27518371912133274541



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.







Mary M Rozenman - New York, NY | Intelius



























Sign In



We found Mary M Rozenman in New York, NY


Mary M Rozenman

                                                                                       Intelius found that Mary M Rozenman  is  a female between 30 and 40 years old from New York, NY.  We have connected them to
                7 addresses,
                4 phones,
                and 0 relatives or associates.
         






Get Report Now

Age

Mary M Rozenman is in her 30s

Mary Has Lived In

New York, NY
San Mateo, CA
San Francisco, CA







Mary M Rozenman



Zodiac SignAquarius



GenderFemale



Professional Status
Vice President at Longitude Capital



Get Report Now










Want to know more about Mary? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Mary, or use our people search engine to find others.
Get Background Check on Mary M Rozenman
Get a Criminal Check on Mary M Rozenman
Get a Public Record Report on Mary M Rozenman
Get a People Search Report on Mary M Rozenman


Mary M Rozenman's Contact Information
Known Cities Lived In
Find out where Mary M Rozenman has lived as well as Mary M Rozenman's phone numbers and email addresses.




Mary M Rozenman Has Lived in 2 States
New York Address for Mary M Rozenman


22 E 1** S* 

New York, NY


Has Lived In

New York, NY
San Mateo, CA


Get Full Address Report










Phone Numbers Associated with Mary M Rozenman

() ***-**** - New York, NY 
(857) ***-**** - New York, NY 
(650) ***-**** - Menlo Park, CA 


Get Full Phone Report



Email Addresses Associated with Mary M Rozenman

m*******n@***.net
m*******n@***.net
m*******n@***.com


Get Email Report




Mary M Rozenman's Professional Information
Information regarding Mary M Rozenman's professional history.  Find out previous places Mary M Rozenman has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Mary M Rozenman Has Worked at 2 Places
Company: Longitude Capital
               Title: Vice President
Company: Allergen NCE Inc
               Title: Senior Vice President Corporate Commercial Development
Mary M Rozenman's Experience
Title: Vice President
               Company: Longitude Capital
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25. Longitude Capital is a private investment firm that focuses on venture growth investments in drug development and medical technology. Founded in 2006, Longitude Capital operates bi-coastally with offices in Menlo Park, CA and Greenwich, CT.  Longitude Capital has over $700 million in assets under management, and most recently raised $385 million for its second fund, Longitude Venture Partners II, L.P., in 2012.
Title: Senior Vice President Corporate Commercial Development
               Company: Allergen NCE Inc
Job Details
               Company Size: Less than $1 mil
Additional Professional Information on Mary M Rozenman

 See Mary M Rozenman's LinkedIn Profile



Mary M Rozenman's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Mary M Rozenman


Mary M Rozenman's known Social Networks And Potential Email Matches

Find all of Mary M Rozenman's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Mary Rozenman
Username Matches

                  MaryRozenman
                  RozenmanMary
                  Mary.Rozenman
                  Rozenman.Mary
                  Mary_Rozenman
                  Rozenman_Mary
                  Mary-Rozenman
                  Rozenman-Mary
                  MRozenman
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
M Rozenman







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.














AIMT Mary M. Rozenman Insider Trades for Aimmune Therapeutics Inc.


































Bulletin

Tobacco stocks crushed by FDA announcement »
        

FDA unveils plan to lower cigarette nicotine content to nonaddictive level »
            




Investor Alert







London Markets Close in:



Currencies
Futures
Metals Stocks


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Aimmune Therapeutics Inc.

                  NASDAQ: AIMT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Aimmune Therapeutics Inc.



Market open
 --Real time quotes
Jul 28, 2017, 10:46 a.m.


AIMT

/quotes/zigman/54531519/composite


$
21.42




Change

-0.01
-0.05%

Volume
Volume 35,810
Real time quotes








/quotes/zigman/54531519/composite
Previous close

$
			21.43
		


$
				21.42
			
Change

-0.01
-0.05%





Day low
Day high
$21.25
$21.70










52 week low
52 week high

            $11.82
        

            $27.31
        


















Insider Activity


Individual




Mary M. Rozenman



Dr. Mary M. Rozenman is Vice President at Longitude Capital Management Co. LLC. She focuses on investments in biotechnology.
Prior to joining Longitude Capital in 2013, Dr. Rozenman was an Associate Principal at McKinsey & Company and a leader in the Healthcare and Corporate Finance practices. At McKinsey, Dr. Rozenman served clients across the biotechnology and medical technology industries on a variety of strategic and operational initiatives across commercial operations, research, clinical and corporate development. Dr Rozenman also led the support of over $6 billion in healthcare transactions for McKinsey's leading private equity clients.
Dr. Rozenman holds a Ph.D in Organic Chemistry and Chemical Biology from Harvard University. She also holds a B.A. in Russian Literature and Biochemistry from Columbia College where she was a John Jay scholar.



Transactions


Date
Shares
Transaction
Value





07/17/2017
300


 
Disposition at $21.38 per share.


6,414


07/17/2017
300


 
Derivative/Non-derivative trans. at $3.02 per share.


906


07/14/2017
5,666


 
Disposition at $21.39 per share.


121,196


07/14/2017
5,666


 
Derivative/Non-derivative trans. at $3.02 per share.


17,111


07/13/2017
8,974


 
Disposition at $21.47 per share.


192,672


07/13/2017
8,974


 
Derivative/Non-derivative trans. at $3.02 per share.


27,101


07/05/2017
15,060


 
Disposition at $21.4 per share.


322,284


07/05/2017
15,060


 
Derivative/Non-derivative trans. at $3.02 per share.


45,481


07/03/2017
30,000


 
Disposition at $20.57 per share.


617,100


07/03/2017
30,000


 
Derivative/Non-derivative trans. at $3.02 per share.


90,600


11/29/2016
129


 



0


11/04/2016
24,096


 
Disposition at $17.6 per share.


424,090


11/04/2016
24,096


 
Derivative/Non-derivative trans. at $3.02 per share.


72,769


10/05/2016
25,000


 
Disposition at $16.8 per share.


420,000


10/05/2016
25,000


 
Derivative/Non-derivative trans. at $3.02 per share.


75,500


09/08/2016
30,000


 
Disposition at $16.8 per share.


504,000


09/08/2016
30,000


 
Derivative/Non-derivative trans. at $3.02 per share.


90,600





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Stephen George Dilly 
President, Chief Executive Officer & Director




Mr. Jeffrey H. Knapp 
Chief Operating Officer




Mr. Eric H. Bjerkholt 
Chief Financial Officer




Ms. Annette  Marcantonio 
Vice President-Clinical Operations




Dr. Daniel C. Adelman 
Chief Medical Officer




Dr. Mary M. Rozenman 
Senior VP-Corporate Development & Strategy




Ms. Susan E. Barrowcliffe 
General Manager-Europe & Senior Vice President




Ms. Le-Van  Nguyen 
Vice President-US Regulatory Affairs




Mr. Gregory  Behar 
Director




Dr. Laura G. Hansen 
Vice President-Investor Relations




Mr. Kenneth F. Boehm 
Vice President-Human Resources




Mr. Douglas T. Sheehy 
Secretary & General Counsel




Mr. William  Turner 
SVP-Global Regulatory Affairs & Quality Assurance




Mr. Mark D. McDade 
Chairman




Mr. Mark T. Iwicki 
Independent Director




Ms. Kathryn E. Falberg 
Independent Director




Ms. Stacey Denenberg Seltzer 
Independent Director




Mr. Patrick G. Enright 
Independent Non-Employee Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:48 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
10:48aInvisalign maker Align stocks surge 8% after earnings blow past estimates
10:47aDow trades flat at 21,790; S&P 500 off 0.4% at 2,466
10:47aNasdaq off 0.3% at 6,359
10:46aBREAKINGDow briefly turns positive as stock market pares opening loss
10:41aJapan slaps 50% tariff on U.S. frozen beef, first such action in 14 years
10:37aPacking the Pounds Back on Pigs
10:34aBREAKINGFDA says it plans to lower nicotine in cigarettes to non-addictive levels
10:30aDollar turns lower for the week following GDP report
10:30aSet yourself up to get the most out of retirement
10:30aTesla earnings: Will Model 3 live up to the hype?
10:29aBitcoin prices rise as Ether extends recent weakness
10:27aTreasury yields dip after second-quarter GDP data
10:26aNew rule forces big car makers into big changes in how they count revenues
10:25aThese are the times you’re actually allowed to put money back into your IRA
10:24aWeekend Sip: Is this the world’s first distilled non-alcoholic spirit?
10:19aU.S. GDP speeds up to 2.6% in 2nd quarter 
10:17aTime for GOP to face reality: Everybody is going to have health insurance
10:06aStock market edges lower, on track for weekly losses 
10:06aHoward Marks says bitcoin isn’t real—and we can all blame millennials for its rise
10:05aMinor lift for final consumer sentiment reading in July as partisan divide remains
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,791.97

-4.58
-0.02%





nasdaq

/quotes/zigman/12633936/realtime
6,355.96

-26.23
-0.41%





s&p 500

/quotes/zigman/3870025/realtime
2,466.36

-9.06
-0.37%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft










Mary M. Rozenman - Publications




















Log In
Sign Up





Log in to add people & connections, or click here to create an account.

 
 Save login 


 - Forgot password
Already have an account? Log in here.Login ID:Password:Re-enter:Email:(Don't worry, your e-mail will not be distributed or made public. Its only purpose is for us to contact you about your account.)


Close
Login
Sign Up






☰
Chemistry Tree 


TreeRecent AdditionsDistanceAnalysisHelpReport BugSign In/Register




  



Mary M. Rozenman, Ph.D. - Publications  

Affiliations: 2008 Harvard University, Cambridge, MA, United States 

Area: The Chemistry of Molecular Evolution                  
   

 
Tree
Info
PubMed Report error 




4 high-probability publications.
We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please
sign in and mark papers as correct or incorrect matches.
If you identify any major omissions or other inaccuracies in the publication list, please let us know.





Year
Citation 
Score


2007
Rozenman MM, Kanan MW, Liu DR. Development and initial application of a hybridization-independent, DNA-encoded reaction discovery system compatible with organic solvents. Journal of the American Chemical Society. 129: 14933-8. PMID 17994738 DOI: 10.1021/ja074155j 
0.96



2007
Rozenman MM, McNaughton BR, Liu DR. Solving chemical problems through the application of evolutionary principles. Current Opinion in Chemical Biology. 11: 259-68. PMID 17548235 DOI: 10.1016/j.cbpa.2007.05.016 
0.96



2006
Rozenman MM, Liu DR. DNA-templated synthesis in organic solvents. Chembiochem : a European Journal of Chemical Biology. 7: 253-6. PMID 16381048 DOI: 10.1002/cbic.200500413 
0.96



2004
Kanan MW, Rozenman MM, Sakurai K, Snyder TM, Liu DR. Reaction discovery enabled by DNA-templated synthesis and in vitro selection. Nature. 431: 545-9. PMID 15457254 DOI: 10.1038/nature02920 
0.96


Show low-probability matches.




 












See Remarks of Aimmune Therapeutics (NASDAQ:AIMT), Rozenman Mary M., sells 30,000 shares worth 7,178








































Stay Connected

Latest Posts in RSS

BusinessEntertainmentFeatured NewsFeatured Press ReleaseFinanceHealthLifestyleNationNon FirstPageOriginalPress ReleaseReviewShoppingSportsStocksTechnologyTravelWorld


Latest Comments in RSS


 / 













EmpoweredNews
World News Summary Helping You Stay Informed









Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping




Our Writers
About Us
Privacy Policy
Contact Us
Advertise
Press Releases
















See Remarks of Aimmune Therapeutics (NASDAQ:AIMT), Rozenman Mary M., sells 30,000 shares worth $617,178
According to Aimmune Therapeutics's most recent Form 4 filing with the SEC dated Jul 06 05:01 PM, company See Remarks, Rozenman Mary M. disclosed selling 30,000 shares at a cost of $20.57. At the time of this transaction (Jul 03), this trade was worth $617,178 in total. As of Jul 03, Rozenman Mary M. now owns 129 shares in total worth about $2,675.46. 
For the last few recent trades made by Aimmune Therapeutics (NASDAQ:AIMT) See Remarks, Rozenman Mary M., we have the following information:




SEC Form 4 filing: Jul 05: Sold 15,060 shares at the rate of $21.40 per share. Total worth of this trade was $322,212. Total number of shares owned as of Jul 05 were 129
SEC Form 4 filing: Nov 04: Sold 24,096 shares at the rate of $17.60 per share. Total worth of this trade was $424,090. Total number of shares owned as of Nov 04 were 0
SEC Form 4 filing: Oct 05: Sold 25,000 shares at the rate of $16.80 per share. Total worth of this trade was $420,000. Total number of shares owned as of Oct 05 were 0




					Posted by  



George Daniels 

					
					on Thursday July 06 2017, 10:14 PM EDT. 

All trademarks acknowledged. 
Filed under Stocks.

	Comments and Trackbacks closed.	
 Follow responses: 
RSS 2.0




Comments are closed


 Latest News 
President & CEO of Sarepta Therapeutics (NASDAQ:SRPT), Ingram Douglas S, buys 47,058 shares worth $1,999,965
Director of Northwest Bancshares (NASDAQ:NWBI), Tredway Philip M, sells 13,560 shares worth $218,667
President of County Bancorp (NASDAQ:ICBK), Schneider Timothy J., sells 543 shares worth $13,575
CEO & Chairman of Opko Health (NASDAQ:OPK), Frost Phillip Md Et Al, buys 23,600 shares worth $149,687
Director of Bryn Mawr Bank Corporation (NASDAQ:BMTC), Gilbert Andrea F, sells 1,775 shares worth $78,264
Former 10% Owner of Internap Corporation (NASDAQ:INAP), Park West Asset Management Llc, sells 2,250,000 shares worth $8,723,250
Chairman of the Board and CEO of Salesforce (NYSE:CRM), Benioff Marc, sells 10,000 shares worth $908,911
Pres., Sales & Cust. Success of Salesforce (NYSE:CRM), Martinez Maria, sells 10,000 shares worth $920,007
Chief Executive Officer of Salem Media Group (NASDAQ:SALM), Atsinger Edward G Iii, sells 483 shares worth $3,598
SVP & Chief Accounting Officer of CoBiz Financial Inc (NASDAQ:COBZ), Dumlao Troy, sells 493 shares worth $8,923

 


News Categories 
Business (7)

Stocks (15,599)



Entertainment (1,297)

Featured News (3,486)

Featured Press Release (254,214)

Finance (309)

Health (653)

Lifestyle (19)

Nation (90)

Non FirstPage (2)

Original (47)

Press Release (17)

Review (1)

Shopping (267)

Sports (613)

Technology (194)

Travel (286)

World (1,367)


  Featured Press Releases 
Catheters Market Growing at Steady CAGR to 2024
Biotechnology Market Set to Register 9.9% CAGR During 2017-2024
3D Laser Scanners Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2022
Yoga Mat Industry Overview by Manufacturers, Regions, Applications, Types, Forecast to 2022
Particle Size Analyzers Industry Overview by Manufacturers, Regions, Applications, Types, Forecast to 2022
Body Fat Measurement Market Trend to 2024 Profiling GE Healthcare, COSMED and Tanita Corporation & More
Global France Homeland Security & Public Safety Market Research Report 2017 Analysis and Forecast to 2022
Asia-Pacific 3DTV Market Analysis by Key Player Samsung, LG Corp ,Sony Corp  and Forecast to 2017-2022
OTC Drug Market Trends Global Industry Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2022
New Research Report: Inkjet Marking Coding Machines Sales market analysis forecast to 2022







Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping
 

About Us
Contact Us
Privacy Policy
Advertise
Press Releases
Terms Of Service
 
Log in 






















Rozenman Mary M. - Aimmune Therapeutics Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsRozenman Mary M.Aimmune Therapeutics (AIMT)See RemarksRanked #15,630 out of 33,852 Insiders on TipRanksRozenman Mary M.'s PerformanceProfitable Transactions0 out of 2 profitable transactionsAverage  Return+0.0%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Most Profitable Insider TradeStock: Aimmune Therapeutics (AIMT)Transaction Type: Informative BuyDates: Jul 17, 2017 - TodayGain: +0.0%See the Latest Stocks Traded by Insiders > Rozenman Mary M.'s Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateAIMTAimmune TherapeuticsSee Remarks-Uninformative Sell$320,135.12Jul 17, 2017Success Rate on Stock0 out of 2 profitable transactions on AIMTAverage Profit on StockAverage return per transaction on AIMT 0.0% Track Record Showing:All TransactionsInformative TransactionsDateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Jul 17, 2017 Informative Buy $45K 14,940 (undisclosed) 0.00%  Jul 06, 2017 Informative Buy $136K 45,060 (undisclosed) 0.00% Show MoreSee All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























